Do post-approval phase III trials for accelerated approved cancer drugs violate equipoise?

6026 Background: Since 1992, the Food and Drug Administration (FDA) has allowed accelerated approval of novel cancer drugs based on improvements in surrogate outcomes, provided that subsequent phas...